We are live on
!
Find out more
Voloridge Investment Management Portfolio holdings
AUM
$25B
1-Year Est. Return
28.08%
This Fund
S&P 500
This Quarter
Est. Return
+24.52%
1 Year Est. Return
+28.08%
3 Year Est. Return
+85.2%
5 Year Est. Return
+73.43%
10 Year Est. Return
+582.16%
AUM
$11.9B
AUM Growth
-$101M
(-0.84%)
Cap. Flow
-$1.72B
Cap. Flow
% of AUM
-14.47%
Top 10 Holdings %
Top 10 Hldgs %
16.8%
Holding
1,692
New
482
Increased
315
Reduced
482
Closed
413
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$242M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$187M |
| 3 |
AstraZeneca
AZN
|
+$163M |
| 4 |
Lockheed Martin
LMT
|
+$162M |
| 5 |
S&P Global
SPGI
|
+$125M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Citigroup
C
|
+$234M |
| 2 |
Johnson & Johnson
JNJ
|
+$185M |
| 3 |
Mercado Libre
MELI
|
+$136M |
| 4 |
Procter & Gamble
PG
|
+$128M |
| 5 |
Shopify
SHOP
|
+$126M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.38% |
| 2 | Healthcare | 15.54% |
| 3 | Consumer Discretionary | 12.1% |
| 4 | Industrials | 11.12% |
| 5 | Communication Services | 10.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
701
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.21M | 0.02% |
25,735
-41,261
| -62% | -$3.5M |
|
702
Rollins
ROL
$17.4B
| $2.2M | 0.02% |
56,265
-316,812
| -85% | -$12.3M |
|
703
Nabors Industries
NBR
$1.35B
| $2.19M | 0.02% |
+37,693
| New | +$1.66M |
|
704
FirstCash
FCFS
$9.14B
| $2.19M | 0.02% |
31,274
-58,250
| -65% | -$3.69M |
|
705
Coca-Cola Europacific Partners
CCEP
$47.5B
| $2.18M | 0.02% |
43,799
+11,600
| +36% | +$490K |
|
706
Carvana
CVNA
$81B
| $2.18M | 0.02% |
45,470
-321,210
| -88% | -$14.7M |
|
707
Arcturus Therapeutics
ARCT
$223M
| $2.18M | 0.02% |
+50,151
| New | +$3.4M |
|
708
TG Therapeutics
TGTX
$7.34B
| $2.17M | 0.02% |
+41,814
| New | +$1.41M |
|
709
Red Robin
RRGB
$183M
| $2.17M | 0.02% |
+113,021
| New | +$1.9M |
|
|
USCR
710
DELISTED
U S Concrete, Inc.
USCR
| $2.17M | 0.02% |
54,197
+329
| +0.6% | +$11.7K |
|
711
Meritage Homes
MTH
$4.8B
| $2.15M | 0.02% |
52,044
-12,290
| -19% | -$581K |
|
712
TripAdvisor
TRIP
$1.29B
| $2.15M | 0.02% |
74,788
-213,001
| -74% | -$5.13M |
|
|
DBD
713
DELISTED
Diebold Nixdorf Incorporated
DBD
| $2.13M | 0.02% |
+199,746
| New | +$1.81M |
|
714
Huntington Bancshares
HBAN
$35.9B
| $2.13M | 0.02% |
+168,415
| New | +$1.91M |
|
|
KC
715
Kingsoft Cloud Holdings
KC
$3.42B
| $2.13M | 0.02% |
+48,813
| New | +$1.81M |
|
|
NBIS
716
Nebius Group N.V.
NBIS
$69.3B
| $2.12M | 0.02% |
30,466
-299,809
| -91% | -$19.1M |
|
|
LTC
717
LTC Properties
LTC
$2.1B
| $2.12M | 0.02% |
54,389
-25,648
| -32% | -$943K |
|
718
Keurig Dr Pepper
KDP
$42.3B
| $2.11M | 0.02% |
66,001
-645,467
| -91% | -$19.1M |
|
719
Enanta Pharmaceuticals
ENTA
$391M
| $2.11M | 0.02% |
50,052
+799
| +2% | +$35.2K |
|
720
Entegris
ENTG
$25B
| $2.1M | 0.02% |
+21,892
| New | +$1.91M |
|
721
SLM Corp
SLM
$5.22B
| $2.1M | 0.02% |
+169,673
| New | +$1.78M |
|
|
AERI
722
DELISTED
Aerie Pharmaceuticals
AERI
| $2.09M | 0.02% |
154,942
-50,228
| -24% | -$607K |
|
723
Marcus Corp
MCS
$929M
| $2.08M | 0.02% |
154,343
+78,185
| +103% | +$791K |
|
724
Abbott
ABT
$193B
| $2.08M | 0.02% |
+18,998
| New | +$2.07M |
|
|
BEAT
725
DELISTED
BioTelemetry, Inc.
BEAT
| $2.08M | 0.02% |
28,840
-6,311
| -18% | -$330K |
|
Similar funds
VAI
JG
OAG
Voloridge Investment Management's Q4 2020 Portfolio in Review
As of Q4 2020, Voloridge Investment Management held 1,692 positions worth $11.9B, down 0.84% from $12B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Voloridge Investment Management withdrew a net $1.72B in Q4 2020, closing 413 positions and reducing 482 holdings. Its most notable exit was Wells Fargo, an estimated $111M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Voloridge Investment Management opened a new position in AstraZeneca worth $154M.
- Voloridge Investment Management's largest Q4 2020 buy was AstraZeneca: 1,542,881 shares worth $154M.
- Voloridge Investment Management added most to Microsoft in Q4 2020, an estimated $242M increase.
- Voloridge Investment Management's biggest Q4 2020 reduction was Citigroup, cutting an estimated $234M.
- Voloridge Investment Management fully exited Wells Fargo in Q4 2020, selling an estimated $111M.
- Voloridge Investment Management's ten largest holdings make up 17% of its $11.9B portfolio in Q4 2020.
- Voloridge Investment Management opened 482 new positions and closed 413 in Q4 2020.
- Voloridge Investment Management's portfolio value fell 0.84% quarter-over-quarter to $11.9B.
Based on Voloridge Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.